Medical Network News 6 January 2015, the pharmaceutical distribution business, it may not be easy, around the base of non-drug-based medicine tender turtle speed ahead, Medicare Drug bidding stalled, distribution rate of non-compliance blacklist system is implemented, net sales Prescription drugs ban ...... more tragic it is that the industry overall sales volume growth of hidden water, industry growth has been declining. These factors accelerate industry reshuffle Forced: in the terminal area hospital, those distribution companies small and scattered, the future want from the large and giant bowl grab something to eat is not easy; in retail terminal, prescription drug sales network The lifting of the ban could smash their jobs entity retailers.
 
Forced to shuffle growth decline
 
Ministry of Commerce issued a "drug distribution industry Blue Book" to make medicine circulation shudder. In 2013, total sales of the pharmaceutical distribution industry to 1.3036 trillion yuan, an increase of 16.7%, growth rate down 1.8 percentage points over the same period last year. Scale pharmaceutical distribution industry end-market growth is the main force behind growth, although total sales of drugs in circulation has increased, but the growth rate has been declining, making the industry's circulation of 16,000 more competitive.
 
In Sichuan Kelun Pharmaceutical Co., Ltd. Shin, director of marketing first wavelet opinion, a decline in the growth rate of the industry can best reflect the industry status quo. First wavelet explained that the growth rate has been declining, demonstrating distribution industry is gradually reshuffle, the industry began to group, fine, professional development. "In the process of shuffling, not only from its own characteristics and profits over the fares of distribution companies will gradually be phased out. In other words, the development of circulation industry will be in line with the business 'eight law', that 20% of large distribution companies will control 80% of market share, thereby distribution industry and more chaotic, complicated phenomenon will gradually be improved. "
 
Commerce Department data confirmed the first wavelet viewpoint, circulation of "Pareto's Law" taking its toll. Research results show that the Ministry of Commerce, has become the focus of pharmaceutical distribution in the pharmaceutical industry to improve the fastest growing sub-sectors. In 2013, the main business income of 100 billion yuan of pharmaceutical wholesale enterprises have 12, 50-100 billion company has 11, there are 75 10-50 billion. Among them, the former 100 wholesale business income accounted for 64.28% of the total market size over the same period.
 
Insiders also revealed that seemingly gains, such as rainbow industry sales volume actually hidden moisture. "Total sales increased every year may be an illusion, such as a drug ex-factory price of 5 yuan, to the dealer that sold for $ 8, and then through the hands of the two agents, and finally can be sold for 14 yuan. If the pill after 5 home even more distribution companies, then sales will increase several times. Thus, total sales in the industry and do not represent the substance, on the contrary, sales of these years should be in the fall. "
 
Hengqiang market pattern forming
 
Currently the pharmaceutical distribution industry competition pattern has basically formed. Pharmaceutical distribution business in accordance with domestic strength, the former three industry should be Sinopharm, Shanghai Pharmaceutical and Kyushu, followed by Guangzhou Pharmaceutical, Beijing Traditional Chinese Medicine, Nanjing Pharmaceutical. Analysis of the industry, Hengqiang situation will lead to accelerated differentiation industry, small and scattered distribution business or no rice straw.
 
Sinopharm is the first sales of over 100 billion pharmaceutical distribution business. As SASAC's enterprise, Sinopharm has a good government resources, the vast majority of the total imports of the drug dealers, mainly positioned to do high-end drug distribution business, grab the cake is the most profitable pharmaceutical distribution field. With the advance of medical reform policy since 2009, good government resources, behind the strong market to raise funds and Sinopharm Sinopharm rely on the flow of business continues to accelerate the pace of acquisition of the provinces, and to intensify cooperation, "pharmacy care" and the major hospitals services, fear of the future leader position is difficult to shake.
 
Followed by the Shanghai Pharmaceutical Sinopharm is that it has formed, including research and development, manufacturing and distribution of the whole industry chain of retail business, including pharmaceutical distribution business remains its heavy head, now is accelerating the layout of the national network. Analysis of the industry, in terms of government resources, the Shanghai Pharmaceutical Sinopharm is better, its main markets in the East region, if you want to the country, and Sinopharm equal footing, will take some time.
 
Compared to two or more counterparts, Kyushu advantage is being polished, its original market positioning and identity of its private enterprises, making it embarrassing situation. Kyushu main consignment of medicines in the low-end, go grass roots organizations and the private hospital medicine channels. Insiders Zhong Xiao Ling analysis, Kyushu University Hospital and only opened to the door to bigger, how to penetrate the high-end market, will become Kyushu current problems to be solved.